| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3991236 | Journal of Thoracic Oncology | 2009 | 6 Pages |
Abstract
The addition of gefitinib to first-line chemotherapy improved progression-free survival and overall survival when used as a first-line therapy in never smokers with advanced NSCLC in this retrospective study. A prospective randomized phase III study is needed to confirm this finding.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Chee-Kian MRCP (UK), Su-Pin MRCP (UK), Wan-Teck MRCP (UK), Chee-Keong MRCP (UK), Swan-Swan MRCP (UK), Sze-Huey MSc, Hui-Hua MSc, PhD, Eng-Huat MRCP (UK),